Your browser doesn't support javascript.
loading
Developing and validating a mortality prediction model for ICH in ITP: a nationwide representative multicenter study.
Chong, Shan; Zhao, Peng; Huang, Rui-Bin; Zhou, Hu; Zhang, Jia-Ning; Hou, Ming; Liu, Yi; Yao, Hong-Xia; Niu, Ting; Peng, Jun; Jiang, Ming; Han, Yan-Qiu; Hu, Jian-Da; Zhou, Ze-Ping; Qiu, Lin; Zhang, Lian-Sheng; Wang, Xin; Wang, Hua-Quan; Feng, Ru; Yang, Lin-Hua; Ma, Liang-Ming; Wang, Shun-Qing; Kong, Pei-Yan; Wang, Wen-Sheng; Sun, Hui-Ping; Sun, Jing; Zhou, He-Bing; Zhu, Tie-Nan; Wang, Li-Ru; Zhang, Jing-Yu; Huang, Qiu-Sha; Fu, Hai-Xia; Wu, Ye-Jun; Li, Yue-Ying; Wang, Qian-Fei; Jiang, Qian; Jiang, Hao; Lu, Jin; Huang, Xiao-Jun; Zhang, Xiao-Hui.
Afiliação
  • Chong S; Peking University People's Hospital, Peking University Institute of Hematology, Beijing, China.
  • Zhao P; National Clinical Research Center for Hematologic Disease, Beijing, China.
  • Huang RB; Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
  • Zhou H; Collaborative Innovation Center of Hematology, Peking University, Beijing, China.
  • Zhang JN; Peking University People's Hospital, Peking University Institute of Hematology, Beijing, China.
  • Hou M; National Clinical Research Center for Hematologic Disease, Beijing, China.
  • Liu Y; Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
  • Yao HX; Collaborative Innovation Center of Hematology, Peking University, Beijing, China.
  • Niu T; Department of Hematology, The First Affiliated Hospital of Nanchang University, Nanchang, China.
  • Peng J; Department of Hematology, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China.
  • Jiang M; Peking University Cancer Hospital and Institute, Beijing, China.
  • Han YQ; Department of Hematology, Qilu Hospital, Shandong University, Jinan, China.
  • Hu JD; Department of Geriatric Hematology, Chinese People's Liberation Army General Hospital, Beijing, China.
  • Zhou ZP; Department of Hematology, Hainan General Hospital, Haikou, China.
  • Qiu L; Department of Hemotology, West China Hospital, Sichuan University, Chengdu, China.
  • Zhang LS; Department of Hematology, Qilu Hospital, Shandong University, Jinan, China.
  • Wang X; Department of Hematology, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, China.
  • Wang HQ; Department of Hematology, The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China.
  • Feng R; Fujian Institute of Hematology, Fujian Medical University Union Hospital, Fuzhou, China.
  • Yang LH; Department of Hematology, The Second Affiliated Hospital of Kunming Medical University, Kunming, China.
  • Ma LM; Department of Hematology, The First Hospital of Jilin University, Changchun, China.
  • Wang SQ; Department of Hematology, Lanzhou University Second Hospital, Lanzhou, China.
  • Kong PY; Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, China.
  • Wang WS; Department of Hematology, Tianjin Medical University General Hospital, Tianjin, China.
  • Sun HP; Department of Hematology, Beijing Hospital, Ministry of Health, Beijing, China.
  • Sun J; Department of Hematology, Second Affiliated Hospital of Shanxi Medical University, Taiyuan, China.
  • Zhou HB; Department of Hematology, Affiliated Shanxi Big Hospital of Shanxi Medical University, Taiyuan, China.
  • Zhu TN; Department of Hematology, Guangzhou First People's Hospital, Guangzhou, China.
  • Wang LR; Xinqiao Hospital, The Third Military Medical University, Chongqing, China.
  • Zhang JY; Department of Hematology, Peking University First Hospital, Beijing, China.
  • Huang QS; Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Fu HX; Nanfang Hospital, Nanfang Medical University, Guangzhou, China.
  • Wu YJ; Beijing Luhe Hospital, Capital Medical University, Beijing, China.
  • Li YY; Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Wang QF; Fuxing Hospital, Capital Medical University, Beijing, China.
  • Jiang Q; Department of Hematology, Second Hospital of Hebei Medical University, Shijiazhuang, China; and.
  • Jiang H; Peking University People's Hospital, Peking University Institute of Hematology, Beijing, China.
  • Lu J; Collaborative Innovation Center of Hematology, Peking University, Beijing, China.
  • Huang XJ; Peking University People's Hospital, Peking University Institute of Hematology, Beijing, China.
  • Zhang XH; National Clinical Research Center for Hematologic Disease, Beijing, China.
Blood Adv ; 6(14): 4320-4329, 2022 07 26.
Article em En | MEDLINE | ID: mdl-35679462
Intracranial hemorrhage (ICH) is a rare and life-threatening hemorrhagic event in patients with immune thrombocytopenia (ITP). However, its mortality and related risk factors remain unclear. Herein, we conducted a nationwide multicenter real-world study of ICH in adult ITP patients. According to data from 27 centers in China from 2005 to 2020, the mortality rate from ICH was 33.80% (48/142) in ITP adults. We identified risk factors by logistic univariate and multivariate logistic regression for 30-day mortality in a training cohort of 107 patients as follows: intraparenchymal hemorrhage (IPH), platelet count ≤10 × 109/L at ICH, a combination of serious infections, grade of preceding bleeding events, and Glasgow coma scale (GCS) level on admission. Accordingly, a prognostic model of 30-day mortality was developed based on the regression equation. Then, we evaluated the performance of the prognostic model through a bootstrap procedure for internal validation. Furthermore, an external validation with data from a test cohort with 35 patients from 11 other centers was conducted. The areas under the receiver operating characteristic (ROC) curves for the internal and external validation were 0.954 (95% confidence interval [CI], 0.910-0.998) and 0.942 (95% CI, 0.871-1.014), respectively. Both calibration plots illustrated a high degree of consistency in the estimated and observed risk. In addition, the decision curve analysis showed a considerable net benefit for patients. Thus, an application (47.94.162.105:8080/ich/) was established for users to predict 30-day mortality when ICH occurred in adult patients with ITP.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Púrpura Trombocitopênica Idiopática Tipo de estudo: Clinical_trials / Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Humans Idioma: En Revista: Blood Adv Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Púrpura Trombocitopênica Idiopática Tipo de estudo: Clinical_trials / Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Humans Idioma: En Revista: Blood Adv Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China